News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 3, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
Download
July 20, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
Download
July 19, 2023 12:05 PM
EDT
2023
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
Download
June 29, 2023 4:05 PM
EDT
2023
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Download
June 20, 2023 9:00 AM
EDT
2023
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
Download
May 26, 2023 5:16 PM
EDT
2023
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
Download
May 17, 2023 12:14 PM
EDT
2023
Aurinia Announces 2023 Annual General Meeting Results
Download
May 9, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
Download
May 4, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
Download
May 3, 2023 7:51 AM
EDT
2023
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
Download
May 2, 2023 4:36 PM
EDT
2023
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
Download
May 2, 2023 12:00 PM
EDT
2023
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
Download
April 28, 2023 6:30 AM
EDT
2023
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
Download
April 25, 2023 11:00 AM
EDT
2023
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
Download
April 24, 2023 6:00 AM
EDT
2023
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
Download
April 11, 2023 10:26 AM
EDT
2023
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
Download
April 5, 2023 6:30 AM
EDT
2023
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
Download
April 3, 2023 4:00 PM
EDT
2023
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
March 6, 2023 4:00 PM
EST
2023
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
February 28, 2023 6:00 AM
EST
2023
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
Download
February 24, 2023 6:00 AM
EST
2023
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
Download
February 7, 2023 4:00 PM
EST
2023
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
Download
February 6, 2023 4:00 PM
EST
2023
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
January 24, 2023 4:00 PM
EST
2023
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
Download
January 23, 2023 1:00 PM
EST
2023
Aurinia Announces PTAB Has Terminated Inter Partes Review
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.